Abstract:Abstract Cancer immunotherapy has achieved notable clinical success, yet its broader application is impeded primarily by immune evasion mechanisms, predominantly stemming from factors such as tumor antigen loss, intrinsic low antigen presentation, and the inherent impermeability of current macromolecules, including cells, antibodies, and proteins. Consequently, there exists a pressing demand for more permeable agents that target intracellular components as viable alternatives. Among the various molecular players involved in immune evasion, PTPN1 and PTPN2, two protein tyrosine phosphatases (PTPs), play a non-redundant role in regulating tumor antigen presentation. They achieve this by modulating the JAK/STAT signaling pathway within tumor cells, with their deletion having been demonstrated to enhance MHC-I presentation across various cell types. Furthermore, PTPN1 and PTPN2 also negatively regulate T cell receptor (TCR) signaling in T cells, as supported by genetic studies. Consequently, these two proteins present as promising targets for the development of innovative cancer immunotherapies due to their dual impact on both tumor cells and T cells. Addressing the intrinsic impermeability challenges associated with macromolecules, we embarked on the development of small molecule agents that specifically target PTPN1 and PTPN2, culminating in the successful creation of a low-nanomolar proteolysis targeting chimera (PROTAC), designated as X1. PROTAC X1 exhibits sustained low-nanomolar binding affinity and exceptional selectivity toward PTPN1 and PTPN2 in in vitro settings. Furthermore, it has demonstrated a nano-molar half-maximal degradation concentration (DC50) in Jurkat T cells and numerous cancer cell lines, while concurrently exhibiting efficacy in eliciting TCR signaling and enhancing MHC-I presentation. Additionally, X1-treated CAR-T cells exhibited augmented cytotoxicity through increased IFN-γ secretion, thereby reinforcing its efficacy in T cell activation. To ascertain the anti-tumor efficacy of X1, we administered X1 to C57BL/6 mice bearing MC38 tumors, resulting in a significant retardation of tumor progression. Subsequent investigations revealed that X1 treatment induced an inflammatory response in the tumor microenvironment, characterized by enhanced T cell infiltration and the activation of CD8+ T cells. Notably, no discernible adverse effects, such as autoimmune symptoms, were observed during treatment. Collectively, these findings indicate that X1 represents a potent and safe agent for cancer immunotherapy. This study not only elucidates the mechanism of action of PTPN1B/TC-PTP pharmacological degradation as a viable approach for cancer treatment but also solidifies the potential of PTPN1B/TC-PTP degradation as a novel avenue for cancer immunotherapy. Citation Format: Zihan Qu, Yunpeng Bai, Jiajun Dong, Zheng Zhang, Bo Huang, Yiming Miao, Andy W. Tao, Philip S. Low, Zhong-Yin Zhang. Discovery of a cebrelon-based PTPN1/PTPN2 dual targeting degrader for cancer immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4505.

Abstract P05: Novel PROTAC-based EZH2 Degraders Effectively Target Lymphoid Malignancies by Depleting Enzyme-Independent Functions of EZH2

Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2

Design, synthesis and evaluation of EZH2-based PROTACs targeting PRC2 complex in lymphoma

Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2

Abstract LB-A09: EED Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex

Targeting Triple-Negative Breast Cancer by a Novel Proteolysis Targeting Chimera Degrader of Enhancer of Zeste Homolog 2

EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex

Discovery of Precision Targeting EZH2 Degraders for Triple-Negative Breast Cancer

Chemically induced degradation of PRC2 complex by EZH2-Targeted PROTACs via a Ubiquitin-Proteasome pathway

Design, Synthesis, and Evaluation of VHL-Based EZH2 Degraders to Enhance Therapeutic Activity Against Lymphoma

Abstract 4513: Exploration degradation of intrinsically disordered protein YAP induced by PROTACs

Distinct Amino Acid-Based PROTACs Target Oncogenic Kinases for Degradation in Non-Small Cell Lung Cancer (NSCLC)

Regulation of EZH2 protein stability: new mechanisms, roles in tumorigenesis, and roads to the clinic

Abstract 4505: Discovery of a cebrelon-based PTPN1/PTPN2 dual targeting degrader for cancer immunotherapy

EZH2 PROTACs target EZH2- and FOXM1-associated oncogenic nodes, suppressing breast cancer cell growth

Abstract 4514: Discovery of potent and orally bioavailable degraders of HPK1 based on a novel HPK1 binder

Abstract B254: Targeted Disruption of the EZH2-EED Complex Inhibits EZH2-dependent Cancer.

Proteolysis Targeting Chimera (Protac) For Epidermal Growth Factor Receptor Enhances Anti-Tumor Immunity In Non-Small Cell Lung Cancer

Abstract 533: Attenuating EZH2-mediated metastasis and tumor growth by pharmacological-based approaches using three-dimensional in vitro culture models

Inhibition of the Deubiquitinating Enzyme USP47 As a Novel Targeted Therapy for Hematologic Malignancies Expressing Mutant EZH2

Abstract 2016: Combined targeting of epigenetic mechanisms has superior efficacy against human mantle cell lymphoma cells